IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor DC polypeptides, for example, to treat patients afflicted with hemophilia B.
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (en) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (en) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (en)
EP (1) EP2461821A4 (en)
JP (1) JP2013500726A (en)
KR (1) KR20120060209A (en)
CN (1) CN102573890A (en)
AU (1) AU2010278721A1 (en)
BR (1) BR112012002072A2 (en)
CA (1) CA2769258A1 (en)
CL (1) CL2012000238A1 (en)
CR (1) CR20120052A (en)
CU (3) CU20120018A7 (en)
DO (1) DOP2012000030A (en)
EA (1) EA201290069A1 (en)
EC (1) ECSP12011637A (en)
GT (1) GT201200023A (en)
IN (1) IN2012DN00908A (en)
MX (1) MX2012001346A (en)
PE (1) PE20121643A1 (en)
SG (1) SG178119A1 (en)
WO (1) WO2011014890A1 (en)
ZA (1) ZA201200716B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (en) 2006-12-15 2014-10-03 Baxter Int SIALYTIC VIIA-ACID (POLY) CONJUGATE FACTOR WITH LONG-TERM LIFE TIME EXTENSION IN VIVO
TR201813067T4 (en) 2008-09-15 2018-09-21 Uniqure Biopharma B V The factor IX polypeptide mutant, its uses and a method for producing it.
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (en) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド Glycopolysial oxidation of non-blood clotting proteins
ES2597954T3 (en) 2009-07-27 2017-01-24 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TR201908836T4 (en) * 2010-07-30 2019-07-22 Baxalta GmbH Nucleophilic catalysts for oxime bond.
BR112013015898A2 (en) 2010-12-22 2018-06-26 Baxter International Inc. water soluble fatty acid derivative, and methods for preparing a fatty acid derivative and a conjugated therapeutic protein.
RU2617764C2 (en) * 2011-12-19 2017-04-26 Дилафор Аб Non-anticoagulant glycosaminoglycans with repeating disaccharide units, and their medical application
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
US10105447B2 (en) * 2013-03-13 2018-10-23 Elanco Us Inc. Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
CN109789181A (en) * 2016-07-27 2019-05-21 费城儿童医院 Composition and method for regulatory factor IX function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (en) * 2003-12-03 2006-08-23 Neose Technologies Inc Glycopegylated factor ix.
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CU20120018A7 (en) 2012-06-21
MX2012001346A (en) 2012-02-17
EP2461821A4 (en) 2013-07-03
CU20130058A7 (en) 2013-06-28
BR112012002072A2 (en) 2016-11-08
ECSP12011637A (en) 2012-02-29
CN102573890A (en) 2012-07-11
EA201290069A1 (en) 2012-07-30
WO2011014890A1 (en) 2011-02-03
CR20120052A (en) 2012-06-04
CU20130057A7 (en) 2013-06-28
JP2013500726A (en) 2013-01-10
GT201200023A (en) 2014-01-27
EP2461821A1 (en) 2012-06-13
ZA201200716B (en) 2013-07-31
SG178119A1 (en) 2012-03-29
US20120164130A1 (en) 2012-06-28
DOP2012000030A (en) 2012-02-29
CA2769258A1 (en) 2011-02-03
AU2010278721A1 (en) 2012-02-16
PE20121643A1 (en) 2012-11-25
CL2012000238A1 (en) 2012-10-05
KR20120060209A (en) 2012-06-11

Similar Documents

Publication Publication Date Title
IN2012DN00908A (en)
MX2011007930A (en) Crystalline insulin-conjugates.
MY192475A (en) Modified factor ix polypeptides and uses thereof
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (en) Peptidomimetic macrocycles.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
IN2012DN03883A (en)
IN2012DN02735A (en)
MY160773A (en) Oxyntomodulin peptide analogue
JO3635B1 (en) Solid pharmaceutical compositions and processes for their production
MX2013009175A (en) Compositions comprising peroxy î±-ketocarboxylic acid and methods for producing and using the same.
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
EP2663576A2 (en) Novel wnt compositions and therapeutic uses of such compositions
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
MX356755B (en) Fumigillol type compounds and methods of making and using same.
MX2010010457A (en) Recombinant rhinovirus vectors.
MX359181B (en) Collagen hydrolysate and use thereof.
MX2012013875A (en) Peripheral blood sparc antibodies and uses thereof.
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2011008179A (en) Peptides for vaccine.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE